IL-28 Supplants Requirement for T(reg) Cells in Protein Sigma1-mediated Protection Against Murine Experimental Autoimmune Encephalomyelitis (EAE)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Jan 22

PMID 20090936

Citations 14

Authors

Agnieszka Rynda

Massimo Maddaloni

Javier Ochoa-Reparaz

Gayle Callis

David W Pascual

Affiliations

Soon will be listed here.

Abstract

Conventional methods to induce tolerance in humans have met with limited success. Hence, efforts to redirect tolerogen uptake using reovirus adhesin, protein sigma 1 (psigma1), may circumvent these shortcomings based upon the recent finding that when reovirus psigma1 is engineered to deliver chicken ovalbumin (OVA) mucosally, tolerance is obtained, even with a single dose. To test whether single-dose tolerance can be induced to treat EAE, proteolipid protein (PLP(130-151)) was genetically fused to OVA to psigma1 (PLP:OVA-psigma1) and shown to significantly ameliorate EAE, suppressing proinflammatory cytokines by IL-10(+) forkhead box P3 (FoxP3)(+) CD25(+)CD4(+) T(reg) and IL-4(+)CD25(-)CD4(+) Th2 cells. IL-10R or IL-4 neutralization reversed protection to EAE conferred by PLP:OVA-psigma1, and adoptive transfer of Ag-specific T(reg) or Th2 cells restored protection against EAE in recipients. Upon assessment of each relative participant, functional inactivation of CD25 impaired PLP:OVA-psigma1's protective capacity, triggering TGF-beta-mediated inflammation; however, concomitant inactivation of TGF-beta and CD25 reestablished PLP:OVA-psigma1-mediated protection by IL-28-producing FoxP3(+)CD25(-)CD4(+) T cells. Thus, psigma1-based therapy can resolve EAE independently of or dependently upon CD25 and assigns IL-28 as an alternative therapy for autoimmunity.

Citing Articles

Safety of Exposure to 0.2 T and 4 Hz Rotating Magnetic Field: A Ten-Month Study on C57BL/6 Mice.

Yang H, Han Y, Zhou C, Nie S, Li M, Yu Q Curr Issues Mol Biol. 2024; 46(7):6390-6406.

PMID: 39057024 PMC: 11275342. DOI: 10.3390/cimb46070382.

Recombinant MBP-pσ1 expressed in soybean seeds delays onset and reduces developing disease in an animal model of multiple sclerosis.

Robles L, Reichenberg L, Grissom J, Chi R, Piller K Plant Biotechnol (Tokyo). 2023; 39(4):367-379.

PMID: 37283612 PMC: 10240915. DOI: 10.5511/plantbiotechnology.22.0926a.

Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Moorman C, Sohn S, Phee H Front Immunol. 2021; 12:657768.

PMID: 33854514 PMC: 8039385. DOI: 10.3389/fimmu.2021.657768.

Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4 T cell apoptosis.

An K, Xue M, Zhong J, Yu S, Lan T, Qi Z J Neuroinflammation. 2020; 17(1):147.

PMID: 32375831 PMC: 7201567. DOI: 10.1186/s12974-020-01829-x.

Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.

Silva R, Greggio S, Venturin G, Da Costa J, Gomez M, Campos M Mol Neurobiol. 2018; 55(12):9307-9327.

PMID: 29667130 DOI: 10.1007/s12035-018-1049-1.

References

Kuchroo V, Das M, Brown J, Ranger A, Zamvil S, Sobel R . B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995; 80(5):707-18. DOI: 10.1016/0092-8674(95)90349-6. View

Ochoa-Reparaz J, Rynda A, Ascon M, Yang X, Kochetkova I, Riccardi C . IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol. 2008; 181(2):954-68. PMC: 2599928. DOI: 10.4049/jimmunol.181.2.954. View

Pillemer B, Qi Z, Melgert B, Oriss T, Ray P, Ray A . STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells. J Immunol. 2009; 183(1):155-63. PMC: 2754746. DOI: 10.4049/jimmunol.0803733. View

Jun S, Gilmore W, Callis G, Rynda A, Haddad A, Pascual D . A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine. J Immunol. 2005; 175(10):6733-40. DOI: 10.4049/jimmunol.175.10.6733. View

Aspord C, Thivolet C . Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol. 2002; 130(2):204-11. PMC: 1906515. DOI: 10.1046/j.1365-2249.2002.01988.x. View

Uze G, Monneron D . IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007; 89(6-7):729-34. DOI: 10.1016/j.biochi.2007.01.008. View

Bergquist C, Johansson E, Lagergard T, Holmgren J, Rudin A . Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun. 1997; 65(7):2676-84. PMC: 175378. DOI: 10.1128/iai.65.7.2676-2684.1997. View

Gonnella P, Kodali D, Weiner H . Induction of low dose oral tolerance in monocyte chemoattractant protein-1- and CCR2-deficient mice. J Immunol. 2003; 170(5):2316-22. DOI: 10.4049/jimmunol.170.5.2316. View

Weiner H . Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997; 18(7):335-43. DOI: 10.1016/s0167-5699(97)01053-0. View

10.

Mennechet F, Uze G . Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006; 107(11):4417-23. DOI: 10.1182/blood-2005-10-4129. View

11.

Ochoa-Reparaz J, Riccardi C, Rynda A, Jun S, Callis G, Pascual D . Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol. 2007; 178(3):1791-9. PMC: 9811398. DOI: 10.4049/jimmunol.178.3.1791. View

12.

Ank N, Paludan S . Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors. 2009; 35(1):82-7. DOI: 10.1002/biof.19. View

13.

Kato H, Fujihashi K, Kato R, Yuki Y, McGhee J . Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses. J Immunol. 2001; 166(5):3114-21. DOI: 10.4049/jimmunol.166.5.3114. View

14.

Coquet J, Chakravarti S, Smyth M, Godfrey D . Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol. 2008; 180(11):7097-101. DOI: 10.4049/jimmunol.180.11.7097. View

15.

Yuki Y, Byun Y, Fujita M, Izutani W, Suzuki T, Udaka S . Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol Bioeng. 2001; 74(1):62-9. DOI: 10.1002/bit.1095. View

16.

Morrow M, Pankhong P, Laddy D, Schoenly K, Yan J, Cisper N . Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009; 113(23):5868-77. PMC: 2700323. DOI: 10.1182/blood-2008-11-190520. View

17.

Bergquist C, Lagergard T, Lindblad M, Holmgren J . Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun. 1995; 63(5):2021-5. PMC: 173259. DOI: 10.1128/iai.63.5.2021-2025.1995. View

18.

Skapenko A, Kalden J, Lipsky P, Schulze-Koops H . The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol. 2005; 175(9):6107-16. DOI: 10.4049/jimmunol.175.9.6107. View

19.

Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y . A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6(11):1133-41. PMC: 1618871. DOI: 10.1038/ni1261. View

20.

Yokoyama Y, Harabuchi Y . Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol. 2002; 63(3):235-41. DOI: 10.1016/s0165-5876(02)00021-6. View